Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib Plus Multi-agent Chemotherapy for New Diagnosed Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
NCT02523976Phase 2Completed
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Aug 2015
- Primary completion
- Dec 2021
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of dasatinib in acute lymphoblastic leukemia (ALL), sponsored by Institute of Hematology and Blood Diseases Hospital. Started Aug 2015; status: completed.
02
Drugs
dasatinib
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT02523976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02523976.